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Abstract
Background: Indonesia has had more recorded human cases of influenza A H5N1 than any other country, with
one of the world’s highest case fatality rates. Understanding barriers to treatment may help ensure life-saving
influenza-specific treatment is provided early enough to meaningfully improve clinical outcomes.
Methods: Data for this observational study of humans infected with influenza A H5N1 were obtained primarily
from Ministry of Health, Provincial and District Health Office clinical records. Data included time from symptom
onset to presentation for medical care, source of medical care provided, influenza virology, time to initiation of
influenza-specific treatment with antiviral drugs, and survival.
Results: Data on 124 human cases of virologically confirmed avian influenza were collected between September
2005 and December 2010, representing 73% of all reported Indonesia cases. The median time from health service
presentation to antiviral drug initiation was 7.0 days. Time to viral testing was highly correlated with starting
antiviral treatment (p < 0.0001). We found substantial variability in the time to viral testing (p = 0.04) by type of
medical care provider. Antivirals were started promptly after diagnosis (median 0 days).
Conclusions: Delays in the delivery of appropriate care to human cases of avian influenza H5N1 in Indonesia
appear related to delays in diagnosis rather than presentation to health care settings. Either cases are not suspected
of being H5N1 cases until nearly one week after presenting for medical care, or viral testing and/or antiviral
treatment is not available where patients are presenting for care. Health system delays have increased since 2007.
Keywords: Influenza A virus H5N1, Delivery of health care, Virulence, Indonesia
Background
Human Avian Influenza represents a major public health
concern due to the high case fatality rate of the disease
coupled with the potential for novel influenza viruses to
cause pandemics. By 21st February 2012, 586 cumulative
cases have been reported globally. Of these, Indonesia
has reported more than any other country. The cumula-
tive number of cases reported from Indonesia by the
same date is 185, or 32% of the world’s cases. Globally
the case fatality rate associated with influenza A H5N1
infection is high, with 346 deaths (59%) reported from
confirmed cases. In Indonesia the case fatality rate is
83% (153/185) [1]. We recently reported the impact of
treatment on the clinical course of influenza H5N1 and
showed that though treatment with oseltamivir within
48 hours offers significant benefits in terms of survival;
the benefits of treatment persist in terms of reduced case
fatality rates, though to a lesser extent, even if treatment
is delayed up to 6 to 8 days after symptom onset [2,3].
Given the very high mortality rates associated with
H5N1 infection in Indonesia and the known association
with delays in initiating treatment, it is important to
determine whether delays occur across the country or
whether some provinces experience longer delays than
others, and whether delays are the result of patients
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delaying seeking health care or whether delays in the
health care service itself are important.
The purpose of this study is to determine whether
delays in treatment in Indonesia result from delays in
presentation for care, subsequent virological testing, or
the timing of the initiation of antiviral drug treatment by
health care providers. We also investigate the association
between province location, demographic and epidemio-
logical characteristics, symptoms at presentation, and
delays in care. To the best of our knowledge this is the
first analysis of health service barriers to care for human
H5N1 cases.
Methods
Data on human avian influenza (H5N1) cases were
collected between September 2005 and December
2010. Most case information came from the Indonesia
Ministry of Health, Provincial and District Health Office
clinical records. The characteristics of some cases were
obtained from literature, and added to registry [4].
Cases were identified through routine surveillance
reports, supplemented by reviews of hospital and clinic
records and laboratory reports. Cases were defined
accordingly to the World Health Organization case
(WHO) guidelines, and through laboratory confirmation
from both Indonesia and WHO laboratories. Data
were collected retrospectively and entered into a
reporting registry [5]. This database included patient
characteristics, clinical, laboratory, exposure, treatment
and outcome information.
For each case the following timelines were determined:
date of symptom onset, date of first presentation to
medical care, date samples were taken for viral testing,
and date of initiation of antiviral drug treatment. The
site of first presentation for medical care was characterized
as one of the following: emergency room, physician’s
office/clinic, rural health service/public health centre, or
other setting. Patient characteristics include age, sex, clin-
ical characteristics of initial disease manifestation, and
history of likely source of exposure to possible sources
of infection with H5N1. Since data were collected
retrospectively from existing data sources, the degree
of completeness was dependent upon the presence of
data in the source record. All signs and symptoms doc-
umented were analysed.
The registry protocol was approved by the ethical review
committee of the University of Indonesia and also by a
central institutional review board in the United States.
Statistical analysis
Cases with missing data on either the time intervals of
interest or the exposure (including cases where the ex-
posure was coded as “not known or not documented”)
were excluded from analyses. The denominator for each
analysis is the number of cases with non-missing values
for the relevant variable. Since time intervals were not
normally distributed, nonparametric statistical tests were
used. For comparisons between two groups the Wilcoxon
Rank Sum test was used; for three groups or more the
Kruskal-Wallis test was used. If the p-value for a Kruskal-
Wallis test was ≤ 0.05, then pair-wise comparisons between
groups were conducted to identify which pairs were
significantly different. A Bonferroni correction for multiple
comparisons was used when reporting results of pair-wise
comparisons. The Spearman rank-order correlation
test was used to examine the relationship between two
continuous variables. Chi-square test was used to test
the association between categorical variables.
Results
This report is based on 124 laboratory confirmed human
avian influenza H5N1 cases for which data were collected
between 1st September 2005 – 31st December 2010. Table 1
summarizes demographic characteristics, presenting clinical
characteristics, and history of exposure to possible sources
of infection with H5N1. These cases represent 73% of all
Indonesia cases reported to WHO over the same time
period. We were unable to retrieve data through case
record retrieval on the remaining 27% of cases.
Location of first presentation for medical care was un-
known for 6 cases. Of the 118 cases with known location,
55% first presented for medical care to a physician’s office
and 21% to an emergency room; the remainder presented
elsewhere. Case fatality appears to differ by type of health
care facility where cases first presented (p = 0.06) (Table 2).
Those presenting to rural health service and public health
centers had the lowest case fatality rate.
Table 1 Demographic and epidemiological characteristics
Demographic and epidemiological
characteristics
Analysis population
(n = 124)
Sex (% male) 54 (43.6%)
Age (median, range) 19.5 (1.5-67)
Exposure n(%)
Any human exposure 8 (6.5%)
Direct poultry exposure 43 (34.7%)
Indirect poultry exposure 29 (23.4%)
Direct wild bird exposure 1 (0.01%)
Indirect wild bird exposure 5 (4.0%)
In vicinity of live poultry 55 (44.4%)
Time from symptom onset to presentation
for medical care (Days) – median (range) n = 114
0 (0-7)
Time from presentation for medical care to
viral testing (Days) – median (range) n = 94
6 (-4.0 -25.0)
Time from presentation for medical care to
antiviral treatment(Days) – median (range) n = 43
7 (1.0-11.0)
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Delays in viral testing and initiation of treatment
Data on time from symptom onset to presentation at
medical care provider were available for 114 cases, of
which 94 cases presented to medical care and underwent
viral testing, and 43 cases who received antiviral treatment.
The median time from symptom onset to presentation was
zero days with a range of zero to 7 days. Although there
were no significant differences for the time from symptom
onset to presentation for medical care between the various
types of health care providers (Table 3), time to viral testing
was significantly different by provider type (p = 0.04).
Overall cases waited 6 days from presentation for medical
care to viral testing. Pair-wise testing showed that the only
statistically significant difference in time to viral testing
was between the emergency room and “Other” groups
(p = 0.01), with patients presenting to other healthcare
providers (consisting of nurses and midwives) experiencing
an average wait of 3.5 days longer than those presenting at
an emergency room. The median time from viral testing to
antiviral treatment was zero days suggesting that viral
testing was coincident with treatment initiation across all
health care providers. Time from presentation for medical
care to viral testing (n = 94), and presentation for medical
care to antiviral treatment (n = 43), were highly correlated
(Spearman’s correlation = 0.88, p < 0.0001). However, none
of the pair-wise comparisons of case fatality rate by health
care facility were statistically significantly different.
No significant difference in time from presentation for
medical care to treatment with oseltamivir (an influenza-
specific antiviral drug) was seen by health care provider type
for the 43 cases for whom data were available. The median
duration from presentation to oseltamivir initiation was 7.0
days (minimum 1.0 days, maximum 11.0 days, Table 3).
Province location and delays
We analyzed delays in presentation, viral testing and
treatment initiation and compared these across eight
Indonesian provinces from which cases were reported.
We found no statistically significant associations with
delays according to province.
Demographic and clinical associations with delays
Neither age nor sex was significantly associated with any
delays in presentation, access to viral testing, or treatment
initiation. With regard to influenza H5N1 from infected
humans, wild birds, and/or poultry, a reduced time to treat-
ment initiation approached statistical significance (p = 0.06)
only for cases who were exposed to other human cases of
H5N1 disease. Of 30 documented signs and symptoms on
presentation, two were associated with delays in both pres-
entation and viral testing: unexplained respiratory illness and
tachypnoea (Table 4). No signs or symptoms were associated
with significantly reduced delays in treatment initiation.
Temporal changes in delays in presentation, viral testing,
and initiation of treatment
Cases who presented with influenza H5N1 in 2005 to
2007 (n = 73) took slightly longer to present for medical
care than cases who developed disease later (n = 51). Con-
versely, the time from presentation to a health care facility
to viral testing and also for treatment initiation was shorter
for cases who were infected in 2005 to 2007 compared with
those infected in more recent years (Table 5).
Discussion
This study represents the first analysis of health system
delays in the clinical management of human H5N1
Table 2 Case fatality rates by location of presentation for
medical care
Location of first presentation
for medical care
N (%) Case fatality
rate (p = 0.06)
Emergency room 25 (21%) 22/25 (88%)
Physician’s office or clinic 65 (55%) 61/65 (94%)
Rural health service/public health center 17 (14%) 12/17 (71%)
Other* 11 (9%) 10/11 (91%)
All** 118 (100%) 105/118 (89%)
*“Other” includes nurse (n = 4) and midwife (n = 7).
**6 cases have unknown location of presentation and are not included in this
table Two of the six cases died; the other four survived.
Table 3 Timing of events by location of first presentation for medical care
Symptom onset to presentation
for medical care
Presentation for medical
care to viral testing
Presentation for medical
care to antiviral treatment
Location of presentation for medical care N (%) Median days (Min, Max) N (%) Median days (Min, Max) N (%) Median days (Min, Max)
Emergency room 24(21) 0.0 (0.0, 7.0) 20 (21) 5.0 (-4.0, 10.0)* 6 (14) 6.5 (2.0, 8.0)
Physician’s office or clinic 62(54) 0.0 (0.0, 7.0) 51 (54) 6.0 (0.0, 25.0) 25 (58) 7.0 (1.0, 10.0)
Rural health service/public health center 17(15) 0.0 (0.0, 7.0) 15 (16) 6.0 (1.0, 11.0) 8 (19) 5.0 (2.0, 11.0)
Other** 11(10) 0.0 (0.0, 4.0) 8 (9) 8.5 (3.0, 9.0) 4(9) 8.0 (5.0, 10.0)
Total 114 0.0 (0.0, 7.0) 94 6.0 (-4.0, 25.0) 43 7.0 (1.0, 11.0)
p = 0.82 p = 0.04 p = 0.68
*Significantly different from other. One case reportedly had a sample drawn for viral testing 4 days before their first reported presentation for medical care. Since
this case was part of a cluster of human cases, it is plausible that the case was tested during an epidemiological investigation and before presenting for
treatment, however, this could not be confirmed. **“Other” includes nurse (n = 4) and midwife (n = 7).
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influenza and shows that, in Indonesia, delays result largely
because of health service limitations rather than patients
delaying seeking care. We found that delays in treatment
are principally a function of health services rather than
delays in patients seeking care. Even in rural settings, pa-
tients present soon after symptoms develop which suggests
that public awareness campaigns regarding H5N1 and
the need for early presentation hve been successful. Early
Table 4 Timing of events by symptom at presentation for medical care
Symptom onset to presentation
for medical care
Presentation for medical
care to viral testing
Presentation for medical
care to antiviral treatment
Symptom noted at first
presentation for medical care
N Median days
(Min, Max)
p-value N Median days
(Min, Max)
p-value N Median days
(Min, Max)
p-value
Fever 93 0.0 (0.0, 7.0) 0.34 76 6.0 (-4.0, 18.0) 0.21 38 6.5 (1.0, 11.0) 0.11
No fever 8 0.0 (0.0, 2.0) 8 7.5 (1.0, 25.0) 2 9.5 (9.0, 10.0)
Unexplained respiratory illness 66 0.0 (0.0, 7.0) 0.05 57 6.0 (0.0, 25.0) 0.04 20 7.0 (1.0, 11.0) 0.71
No unexplained respiratory illness 38 0.0 (0.0, 4.0) 32 7.0 (3.0, 18.0) 22 7.0 (2.0, 11.0)
Excessive sputum 1 0.0 (0.0, 0.0) 0.61 1 7.0 (7.0, 7.0) 0.97 1 7.0 (7.0, 7.0) 0.80
No excessive sputum 50 0.0 (0.0, 7.0) 45 7.0 (0.0, 25.0) 26 8.0 (1.0, 11.0)
Sore throat/pharyngitis 25 0.0 (0.0, 7.0) 0.06 19 5.0 (-4.0, 11.0) 0.14 12 6.0 (1.0, 11.0) 0.69
No sore throat/pharyngitis 44 0.0 (0.0, 7.0) 42 7.0 (0.0, 25.0) 22 7.0 (2.0, 10.0)
Rhinorrhea 2 0.5 (0.0, 1.0) 0.73 2 6.5 (6.0, 7.0) 0.77 2 7.5 (7.0, 8.0) 0.83
No rhinorrhea 66 0.0 (0.0, 7.0) 57 6.0 (0.0, 25.0) 33 7.0 (1.0, 11.0)
Tachypnea 27 1.0 (0.0, 7.0) 0.04 23 5.0 (-4.0, 10.0) < 0.01 6 6.0 (1.0, 11.0) 0.40
No tachypnea 64 0.0 (0.0, 7.0) 57 7.0 (1.0, 25.0) 31 7.0 (2.0, 11.0)
Cyanosis 0 - N/A 0 - N/A 0 - N/A
No cyanosis 56 0.0 (0.0, 7.0) 49 6.0 (0.0, 11.0) 32 7.0 (2.0, 11.0)
Abnormal breath sounds 0 - N/A 0 - N/A 0 - N/A
No abnormal breath sounds 40 0.0 (0.0, 5.0) 36 7.0 (0.0, 11.0) 25 8.0 (2.0, 11.0)
Diarrhea 9 0.0 (0.0, 2.0) 0.43 7 6.0 (3.0, 8.0) 0.70 1 9.0 (9.0, 9.0) 0.47
No diarrhea 70 0.0 (0.0, 7.0) 60 6.0 (0.0, 18.0) 33 7.0 (1.0, 11.0)
Abdominal pain 14 0.5 (0.0, 7.0) 0.20 11 6.0 (3.0, 9.0) 0.89 5 7.0 (5.0, 9.0) 0.98
No abdominal pain 60 0.0 (0.0, 7.0) 53 6.0 (0.0, 18.0) 32 7.0 (1.0, 11.0)
Vomiting 11 0.0 (0.0, 1.0) 0.91 8 6.5 (3.0, 10.0) 0.43 4 8.0 (7.0, 9.0) 0.43
No vomiting 70 0.0 (0.0, 7.0) 62 6.0 (0.0, 25.0) 32 7.0 (1.0, 11.0)
Headache 25 1.0 (0.0, 7.0) < 0.01 21 6.0 (0.0, 9.0) 0.65 8 7.0 (5.0, 10.0) 0.84
No headache 48 0.0 (0.0, 7.0) 41 7.0 (0.0, 25.0) 26 7.5 (1.0, 11.0)
Neurological involvement 0 - N/A 0 - N/A 0 - N/A
No neurological involvement 53 0.0 (0.0, 7.0) 46 7.0 (0.0, 25.0) 28 7.5 (2.0, 11.0)
Psychiatric symptoms 0 - N/A 0 - N/A 0 - N/A
No psychiatric symptoms 43 0.0 (0.0, 5.0) 38 7.0 (0.0, 11.0) 27 8.0 (2.0, 11.0)
Fatigue 11 1.0 (0.0, 4.0) 0.21 10 6.0 (3.0, 7.0) 0.32 4 6.0 (3.0, 7.0) 0.18
No fatigue 58 0.0 (0.0, 7.0) 49 7.0 (0.0, 18.0) 29 7.0 (1.0, 11.0)
Myalgia 6 0.5 (0.0, 2.0) 0.38 5 7.0 (6.0, 9.0) 0.47 2 6.0 (5.0, 7.0) 0.49
No myalgia 51 0.0 (0.0, 7.0) 43 7.0 (0.0, 11.0) 27 8.0 (1.0, 11.0)
Bleeding gums or nose 0 - N/A 0 - N/A 0 - N/A
No bleeding gums or nose 80 0.0 (0.0, 7.0) 69 6.0 (-4.0, 25.0) 35 7.0 (1.0, 11.0)
Enlarged Liver 0 - N/A 0 - N/A 0 - N/A
No enlarged liver 45 0.0 (0.0, 4.0) 37 7.0 (1.0, 11.0) 27 8.0 (2.0, 11.0)
Conjunctivitis 0 - N/A 0 - N/A 0 - N/A
No conjunctivitis 59 0.0 (0.0, 7.0) 51 7.0 (0.0, 25.0) 30 7.0 (2.0, 11.0)
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treatment with oseltamivir is recommended, and delays
beyond 48 hours after symptom onset result in worse
outcomes [3,6,7]. We found that the median time from
health service presentation to antiviral drug initiation
was 7.0 days in Indonesia, and case fatality rates remain
high despite the use of oseltamivir treatment. The delayed
initiation of treatment appears to be an important contribu-
tor to the especially high case fatality rates documented
from Indonesia [8].
Delays in the initiation of influenza specific antiviral
drugs may be the result of either a lack of drugs at sites
of care or a lack of clinical suspicion of H5N1 by the
treating health care workers. The latter seems most
likely, and concurs with other reports suggesting better
clinical outcomes in patients who are part of clusters of
cases where clinical suspicion is likely to be high [4].
Furthermore, H5N1 case-finding has not focused on the
identification of asymptomatic or mild cases of H5N1
virus infection [4,9-11]. Moreover, the Indonesian Ministry
of Health has distributed stockpiles of drugs to all
provincial health offices, referral hospitals, and other
hospitals. Seven million capsules of oseltamivir have
already been distributed to health center level in accord-
ance with the Indonesia Centre for Disease Control (CDC)
guidelines [12].
A low clinical suspicion of disease by health care
workers likely remains an important impediment to early
diagnosis, virological confirmation, and appropriate
treatment initiation [13]. The signs and symptoms during
the first two days of disease in cases reported here were
mostly non-specific. This nonspecific clinical presentation
of influenza A (H5N1) disease raises challenges. The
differential diagnosis of cases may include other influenza-
like illnesses, dengue, or typhoid [14], to the exclusion of
influenza A (H5N1). In an earlier report, only 12% of
influenza H5N1 cases were initially diagnosed as having
influenza H5N1 [13].
Early treatment is important in achieving clinical success
and a high index of clinical suspicion is necessary for pa-
tients presenting, sometimes with non-specific symptoms,
to clinical settings. For any benefits to accrue from prompt
presentation for medical care, clinical suspicion needs
to be raised amongst physicians and other care-givers.
Whilst patients presented earlier for medical care prior
to 2008, perhaps because of the significant investments
in community awareness of avian influenza [15], increasing
delays in viral testing and the initiation of appropriate treat-
ment, irrespective of type of health care setting, appear to
be increasing. The late health care seeking behaviour in
2005-2007 may have resulted from a low level of awareness
in population [16]. By 2009, research suggests, community
awareness in Indonesia had increased [17].
We found that those presenting to rural health services
and public health centres had lower fatality rates than
those presenting to other sites of care (Table 2). This
was a surprising finding. A possible explanation may
be that patients with an obviously poor prognosis may
have been referred to higher level health facilities without
being formally admitted to rural health centres or public
health centres.
There are some limitations in our study. Whilst we
analysed data from 124 out of 171 cases, we could not
collect data for the remaining cases due to administrative
challenges. Since the missing cases mostly are from the
island of Sumatra, these results may not be generalizable to
health care services delays in a a different geographic area.
Although we found that the median time from presenta-
tion to antiviral drug initiation was 7.0 days, some ques-
tions remain unanswered. For example, we have insufficient
data to determine which health care providers are limited
in their capacity to provide prompt treatment for patients,
and why. Most patients (55%) first seek medical treatment
at a physician’s office or clinic and go to the hospital when
the disease becomes severe. But we are not able to offer in-
sights into how the movement of patients between health
care settings influences care provision in terms of delay in
initiation of treatment. Nonetheless, we believe our analyses
provide important insights on delays in presentation from
symptom onset, to viral testing, and to initiation of treat-
ment in Indonesia.
Conclusions
Reducing health care system delays in the initiation of spe-
cific treatment for patients infected with influenza H5N1 is
no easy matter. The non-specific nature of the disease, es-
pecially in the early days, suggests a number of options that
might be considered. The application of rapid diagnostic
tests on presentation to confirm or refute the diagnosis
might enable clinicians to tailor their treatment better.
Alternatively, the initiation of treatment when clinical
Table 5 Timing of events by year of infection
Symptom onset to presentation
for medical care
Symptom onset to viral testing Symptom onset to antiviral treatment
Year of Infection N (%) Median days (Min, Max) N (%) Median days (Min, Max) N (%) Median days (Min, Max)
2005-2007 (n = 73) 63(86) 1.0 (0.0, 7.0) 47(64) 5.0 (-4.0, 25.0) 14 5.0 (1.0, 11.0)
2008-2010 (n = 51) 51(100) 0.0 (0.0, 7.0) 47(92) 7.0 (1.0, 11.0) 29 7.0 (2.0, 11.0)
p = 0.007 p = 0.022 p = 0.012
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suspicion is raised might offer benefits to the minority who
actually have influenza H5N1. Both of these approaches
have cost implications that need to be determined. Pro-
spective clinical studies too may offer more robust data on
clinical symptoms and signs associated with differentiating
H5N1 from other diseases as well as determining those
likely to fare least well clinically and thus benefit most from
influenza specific clinical interventions.
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